Escin Clinical Trials

Size	Price	Qty
100mg	USD 147
500mg	USD 347

Clinical Trials

Multiple clinical trials evaluate the therapeutic potential of escin across diverse inflammatory and postoperative conditions, including hemorrhoids, coronavirus infections, and dental procedure sequelae such as pain, facial edema, and trismus. These investigational protocols span Early Phase 1, Phase 2, and Phase 3 trials, with recruitment statuses ranging from recruiting and enrolling by invitation to completed and unknown. Key academic and institutional sponsors driving these evaluations include Chiang Mai University, the University of L'Aquila, the Oman Medical Speciality Board, the University of Catanzaro, and the University of Science and Technology, Yemen.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07244029	RECRUITING	Postoperative Pain; Facial Swelling; Trismus	Oman Medical Speciality Board	2026-01-01
NCT06748014	ENROLLING_BY_INVITATION	Hemorrhoid	Chiang Mai University	2024-12-20	EARLY_PHASE1
NCT07304882	COMPLETED	Impacted Mandibular Third Molar Extraction; Post Operative Complications	University of Science and Technology, Yemen	2023-11-30	PHASE3
NCT06363513	UNKNOWN	Anorectal Disorder	Chiang Mai University	2024-04
NCT04657874	COMPLETED	Postoperative Pain; Edema; Swelling Lips & Face	University of L'Aquila	2020-12-01
NCT04322344	UNKNOWN	Coronavirus Infections	University of Catanzaro	2020-03-23	PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-01-15)

Check the Escin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Escin acts as a saponin mixture that inhibits endothelial lysosomal enzymes and vascular hyperpermeability, thereby reducing fluid exudation and maintaining microvascular wall integrity. This vasoprotective and anti-inflammatory activity suppresses capillary leakage and tissue swelling, providing a direct biochemical foundation for its clinical use in alleviating postoperative pain, edema, and hemorrhoidal complications.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).